Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 2
1977 3
1978 1
1979 3
1980 1
1981 2
1983 1
1984 1
1985 2
1986 1
1987 2
1988 5
1989 7
1990 10
1991 8
1992 12
1993 16
1994 26
1995 17
1996 16
1997 18
1998 19
1999 21
2000 22
2001 16
2002 23
2003 24
2004 24
2005 23
2006 22
2007 23
2008 30
2009 27
2010 34
2011 33
2012 47
2013 35
2014 56
2015 55
2016 61
2017 61
2018 70
2019 89
2020 78
2021 110
2022 86
2023 73
2024 28

Text availability

Article attribute

Article type

Publication date

Search Results

1,170 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "B-cell adult acute lymphocytic leukemia"
Page 1
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Brown PA, Ji L, Xu X, Devidas M, Hogan LE, Borowitz MJ, Raetz EA, Zugmaier G, Sharon E, Bernhardt MB, Terezakis SA, Gore L, Whitlock JA, Pulsipher MA, Hunger SP, Loh ML. Brown PA, et al. JAMA. 2021 Mar 2;325(9):833-842. doi: 10.1001/jama.2021.0669. JAMA. 2021. PMID: 33651090 Free PMC article. Clinical Trial.
IMPORTANCE: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially fo …
IMPORTANCE: Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in chi …
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E, Short NJ, Jain N, Haddad FG, Welch MA, Ravandi F, Kantarjian H. Jabbour E, et al. J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5. J Hematol Oncol. 2023. PMID: 36927623 Free PMC article. Review.
Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 2022 across ALL subtypes. ...Among patients 6 …
Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis …
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Kantarjian HM, et al. J Clin Oncol. 2000 Feb;18(3):547-61. doi: 10.1200/JCO.2000.18.3.547. J Clin Oncol. 2000. PMID: 10653870 Clinical Trial.
PURPOSE: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a dose-intensive regimen, in adult acute lymphocytic leukemia (ALL). PATIENTS AND METHODS: Adults with new …
PURPOSE: To evaluate the efficacy and toxicity of Hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone), a …
Lymphoblastic Lymphoma: a Concise Review.
Intermesoli T, Weber A, Leoncin M, Frison L, Skert C, Bassan R. Intermesoli T, et al. Curr Oncol Rep. 2022 Jan;24(1):1-12. doi: 10.1007/s11912-021-01168-x. Epub 2022 Jan 20. Curr Oncol Rep. 2022. PMID: 35059993 Review.
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable from acute lymphoblastic leukemia (ALL). ...Stem cell transplantation is effective and should be considered for …
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable …
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD, O'Brien MM. Rubinstein JD, et al. Front Immunol. 2023 Aug 3;14:1237738. doi: 10.3389/fimmu.2023.1237738. eCollection 2023. Front Immunol. 2023. PMID: 37600823 Free PMC article. Review.
InO has shown significant activity in relapsed and refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in both single agent and combination chemotherapy regimens in adult and pediatric trials. Its use in newly diagno …
InO has shown significant activity in relapsed and refractory B-cell precursor acute lymphoblastic leu …
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Clinical Trial.
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive therapy. ...METHODS: For this open-label phase …
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in …
How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia.
Kopmar NE, Cassaday RD. Kopmar NE, et al. Blood. 2023 Mar 23;141(12):1379-1388. doi: 10.1182/blood.2022017035. Blood. 2023. PMID: 36548957 Free PMC article. Review.
The central nervous system (CNS) is the most important site of extramedullary disease in adults with acute lymphoblastic leukemia (ALL). Although CNS disease is identified only in a minority of patients at the time of diagnosis, subsequent CNS relapses …
The central nervous system (CNS) is the most important site of extramedullary disease in adults with acute lymphoblastic …
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ, Sadelain M. Park JH, et al. N Engl J Med. 2018 Feb 1;378(5):449-459. doi: 10.1056/NEJMoa1709919. N Engl J Med. 2018. PMID: 29385376 Free PMC article. Clinical Trial.
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. METHODS: We conduc …
BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B …
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC, Tasian SK. Harvey RC, et al. Blood Adv. 2020 Jan 14;4(1):218-228. doi: 10.1182/bloodadvances.2019000163. Blood Adv. 2020. PMID: 31935290 Free PMC article. Review.
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated …
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of …
Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, Riddell SR, Maloney DG, Boeckh M, Turtle CJ. Hill JA, et al. Blood. 2018 Jan 4;131(1):121-130. doi: 10.1182/blood-2017-07-793760. Epub 2017 Oct 16. Blood. 2018. PMID: 29038338 Free PMC article.
Lymphodepletion chemotherapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy is a novel treatment for refractory or relapsed B-cell malignancies. ...We used Poisson and Cox regression to evaluate pre- and posttreatment risk …
Lymphodepletion chemotherapy with CD19-targeted chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy is a novel treatment …
1,170 results